International consensus group on the evidence-based pharmacologic treatment of bipolar I and II depression

Journal of Clinical Psychiatry

Volumn 69, Issue 10, 2008, Pages 1632-1646

  Kasper, Siegfried ^a   Calabrese, Joseph R ^b   Johnson, Gordon ^c   Tajima, Osamu ^d   Vieta, Eduard ^e   Viguera, Adele C ^f   Yatham, Lakshmi N ^g   Young, Allan H ^g  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d KYORIN UNIVERSITY   (Japan)

^e UNIVERSITY OF BARCELONA   (Spain)

^f LERNER RESEARCH INSTITUTE   (United States)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ARIPIPRAZOLE; FLUOXETINE; ICOSAPENTAENOIC ACID ETHYL ESTER; IMIPRAMINE; LAMOTRIGINE; LITHIUM; MODAFINIL; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PLACEBO; PRAMIPEXOLE; QUETIAPINE; SERTRALINE; VALPROATE SEMISODIUM; VENLAFAXINE;

BIPOLAR DISORDER; CLINICAL TRIAL; DEPRESSION; DOCUMENTATION; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HUMAN; HYPOMANIA; MONOTHERAPY; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 54949139986     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v69n1014     Document Type: Review

References (109)

1. Calabrese JR, Kasper S, Johnson G, et al. International Consensus Group on Bipolar I Depression Treatment Guidelines [ACADEMIC HIGHLIGHTS]. J Clin Psychiatry 2004 Apr;65(4):569-579
2. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2007;64:543-552
3. Perala J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders in a general population. Arch Gen Psychiatry 2007;64:19-28
4. Kasper S, Hirschfeld RMA. Handbook of Bipolar Disorder. New York, NY: Taylor & Francis; 2005
5. Prince M, Patel V, Saxena S, et al. No health without mental health. Lancet 2007;370:859-877
6. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry 2003 Jun;64(6):680-690
7. Judd LL, Akiskal HS, Schettler PJ, et al. Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study. Arch Gen Psychiatry 2005;62:1322-1330
8. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 2002;59:530-537
9. Kupka RW, Altshuler LL, Nolen WA, et al. Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder. Bipolar Disord 2007;9:531-535
10. Vieta E, Benabarre A, Colom F, et al. Suicidal behavior in bipolar I and bipolar II disorder. J Nerv Ment Dis 1997 Jun;185(6):407-409
11. Vieta E, Colom F, Corbella B, et al. Clinical correlates of psychiatric comorbidity in bipolar I patients. Bipolar Disord 2001;3:253-258
12. Keller MB. Prevalence and impact of comorbid anxiety and bipolar disorder. J Clin Psychiatry 2006;67(suppl 1):5-7
13. Perlis RH. Misdiagnosis of bipolar disorder. Am J Manag Care 2005;11:S271-S274
14. Pollack LE, Cramer RD, Varner RV. Psychosocial functioning of people with substance abuse and bipolar disorders. Subst Abus 2000 Sep;21(3):193-203
15. Hirschfeld RM, Lewis L, Vornik LA. Perceptions and impact of bipolar disorder: how far have we really come? results of the National Depressive and Manic-Depressive Association 2000 survey of individuals with bipolar disorder. J Clin Psychiatry 2003 Feb;64(2):161-174
16. Mitchell PB, Goodwin GM, Johnson GF, et al. Diagnostic guidelines for bipolar depression: a probabilistic approach. Bipolar Disord 2008;10:144-152
17. Goodwin FK, Jamison KR. Manic-Depressive Illness: Bipolar Disorders and Recurrent Depression. 2nd ed. New York, NY: Oxford University Press; 2007
18. Srisurapanont M, Yatham LN, Zis AP. Treatment of acute bipolar depression: a review of the literature. Can J Psychiatry 1995;40:533-544
19. Young AH, McElroy S, Chang W, et al. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN I). Presented at the 3rd biennial conference of the International Society for Bipolar Disorders; Delhi and Agra, India; Jan 27-30, 2008
20. Prien RF, Klett CJ, Caffey EM Jr. Lithium prophylaxis in recurrent affective illness. Am J Psychiatry 1974;131:198-203
21. Prien RF, Klett CJ, Caffey EM Jr. Lithium carbonate and imipramine in prevention of affective episodes: a comparison in recurrent affective illness. Arch Gen Psychiatry 1973;29:420-425
22. Geddes JR, Burgess S, Hawton K, et al. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161:217-222
23. Smith LA, Cornelius V, Warnock A, et al. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord 2007;9:394-412
24. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003;60:392-400
25. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003 Sep;64(9):1013-1024
26. Baldessarini RJ, Tondo L. Does lithium treatment still work? evidence of stable responses over three decades. Arch Gen Psychiatry 2000 Feb;57(2):187-190
27. Calabrese JR, Bowden CL, Sachs GS, et al. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 1999 Feb;60(2):79-88
28. Calabrese JR, Huffman RF, White RL, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008;10:323-333
29. Geddes J, Huffman RF, Paksa W, et al. Lamotrigine for acute treatment of bipolar depression: individual patient data meta-analysis of 5 randomised, placebo-controlled trials [abstract]. Bipolar Disord 2007;9(suppl 1):42-43
30. Geddes JR, Calabrese JR, Goodwin GM, et al. Lamotrigine for acute treatment of bipolar depression: individual patient data meta-analysis for 5 randomised controlled trials. Br J Psychiatry. In press
31. Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry 2006 Jul;67(7):1025-1033
32. Goodwin GM, Bowden CL, Calabrese JR, et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004 Mar;65(3):432-441
33. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162:1351-1360
34. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 2006;26:600-609
35. McElroy S, Young AH, Carlsson A, et al. Double-blind, randomized, placebo-controlled study of quetiapine and paroxetine in adults with bipolar depression (EMBOLDEN II). Presented at the 3rd biennial conference of the International Society for Bipolar Disorders; Delhi and Agra, India; Jan 27-30, 2008
36. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Am J Psychiatry 1999;156:702-709
37. Keck PE Jr, Corya SA, Altshuler LL, et al. Analyses of treatment-emergent mania with olanzapine/fluoxetine combination in the treatment of bipolar depression. J Clin Psychiatry 2005 May;66(5):611-616
38. Brown EB, Dunner DL, Adams DH, et al. Olanzapine/fluoxetine combination versus lamotrigine in the long-term treatment of bipolar I depression [poster]. Presented at the 2nd biennial conference of the International Society for Bipolar Disorders; Aug 2-4, 2006; Edinburgh, United Kingdom
39. Nierenberg AA, Ostacher MJ, Calabrese JR, et al. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Am J Psychiatry 2006;163:210-216
40. van der Loos MLM, Mulder P, Hartong EGTM, et al, and the LamLit Study Group. Efficacy and safety of lamotrigine as addon to lithium in the treatment of bipolar depression: a multi-center, double-blind, placebo-controlled trial. J Clin Psychiatry. In press
41. Licht RW. Lamotrigine versus lithium in prophylaxis of bipolar disorder: a randomised study mimicking clinical practice [abstract]. Bipolar Disord 2008;10(suppl 1):27
42. Suppes T, Liu S, Paulsson B, et al. Maintenance treatment in bipolar I disorder with quetiapine concomitant with lithium or divalproex: a North American placebo-controlled, randomized multicenter trial [poster]. Presented at the 46th annual meeting of the American College of Neuropsychopharmacology; Dec 9-13, 2007; Boca Raton, Fla
43. Vieta E, Eggens I, Persson I, et al. Efficacy and safety of quetiapine in combination with lithium or divalproex as maintenance treatment for bipolar I disorder [poster]. Presented at the 20th European College of Neuropsychopharmacology Congress; Oct 13-17, 2007; Vienna, Austria
44. Nemeroff CB, Evans DL, Gyulai L, et al. Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression. Am J Psychiatry 2001;158:906-912
45. Davis LL, Bartolucci A, Petty F. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 2005;85:259-266
46. Ghaemi SN, Gilmer WS, Goldberg JF, et al. Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study. J Clin Psychiatry 2007 Dec;68(12):1840-1844
47. Post RM, Uhde TW, Roy-Byrne PP, et al. Antidepressant effects of carbamazepine. Am J Psychiatry 1986;143:29-34
48. Cohn JB, Collins G, Ashbrook E, et al. A comparison of fluoxetine, imipramine and placebo in patients with bipolar depressive disorder. Int Clin Psychopharmacol 1989;4:313-322
49. Post RM, Altshuler LL, Leverich GS, et al. Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline. Br J Psychiatry 2006;189:124-131
50. Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007;164:1242-1249
51. Goldberg JF, Burdick KE, Endick CJ. Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression. Am J Psychiatry 2004;161:564-566
52. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006;188:46-50
53. Gijsman HJ, Geddes JR, Rendell JM, et al. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry 2004;161:1537-1547
54. Sachs GS, Nierenberg A, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med 2007;356:1711-1722
55. Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20
56. Vieta E, Suppes T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord 2008;10:163-178
57. Coryell W, Endicott J, Andreasen N, et al. Bipolar I, bipolar II, and nonbipolar major depression among the relatives of affectively ill probands. Am J Psychiatry 1985;142:817-821
58. Vieta E, Gasto C, Otero A, et al. Differential features between bipolar I and bipolar II disorder. Compr Psychiatry 1997;38:98-101
59. Benazzi F. A comparison of the age of onset of bipolar I and bipolar II outpatients. J Affect Disord 1999;54:249-253
60. Judd LL, Akiskal HS, Schettler PJ, et al. The comparative clinical phenotype and long term longitudinal episode course of bipolar I and II: a clinical spectrum or distinct disorders? J Affect Disord 2003;73:19-32
61. Suppes T, Hirschfeld RM, Vieta E, et al. Quetiapine for the treatment of bipolar II depression: analysis of data from two randomized, double-blind, placebo-controlled studies [online ahead of print May 11, 2007]. World J Biol Psychiatry. doi:10.1080/15622970701317265
62. Zarate CA Jr, Payne JL, Singh J, et al. Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol Psychiatry 2004;56:54-60
63. Parker G, Tully L, Olley A, et al. SSRIs as mood stabilizers for bipolar II disorder? a proof of concept study. J Affect Disord 2006 Jun;92(2-3):205-214
64. Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry 2005;162:2152-2161
65. Calabrese JR, Suppes T, Bowden CL, et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry 2000 Nov;61(11):841-850
66. Vieta E, Calabrese JR, Goikolea JM, et al. Quetiapine monotherapy in the treatment of patients with bipolar I or II depression and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled study. Bipolar Disord 2007;9:413-425
67. Leibenluft E. Women with bipolar illness: clinical and research issues. Am J Psychiatry 1996;153:163-173
68. Viguera AC, Cohen LS, Baldessarini RJ, et al. Managing bipolar disorder during pregnancy: weighing the risks and benefits. Can J Psychiatry 2002;47:426-436
69. Lier L, Kastrup M, Rafaelsen O. Psychiatric illness in relation to pregnancy and childbirth: diagnostic profiles, psychosocial and perinatal aspects. Nord Psykiatr Tidsskr 1989;43:535-542
70. Grof P, Robbins W, Alda M, et al. Protective effect of pregnancy in women with lithium-responsive bipolar disorder. J Affect Disord 2000;61:31-39
71. Blehar MC, DePaulo JR Jr, Gershon ES, et al. Women with bipolar disorder: findings from the NIMH Genetics Initiative sample. Psychopharmacol Bull 1998;34:239-243
72. Freeman MP, Smith KW, Freeman SA, et al. The impact of reproductive events on the course of bipolar disorder in women. J Clin Psychiatry 2002 Apr;63(4):284-287
73. Viguera AC, Whitfield T, Baldessarini RJ, et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation. Am J Psychiatry 2007;164:1817-1824
74. Viguera AC, Nonacs R, Cohen LS, et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance. Am J Psychiatry 2000;157:179-184
75. Newport DJ, Pennell PB, Calamaras MR, et al. Lamotrigine in breast milk and nursing infants: determination of exposure [published online ahead of print June 30, 2008]. Pediatrics 2008 Jul;122(1):e223-231
76. Yonkers KA, Wisner KL, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004;161:608-620
77. Newport DJ, Stowe ZN, Viguera AC, et al. Lamotrigine in bipolar disorder: efficacy during pregnancy. Bipolar Disord 2008;10:432-436
78. Cohen LS, Friedman JM, Jefferson JW, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994;271:146-150
79. Meador KJ, Baker GA, Finnell RH, et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 2006;67:407-412
80. Vajda FJ, Hitchcock A, Graham J, et al. The Australian Register of Antiepileptic Drugs in Pregnancy: the first 1002 pregnancies. Aust N Z J Obstet Gynaecol 2007;47:468-474
81. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004;61:673-678
82. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005;64:961-965
83. Morrow J, Russell A, Guthrie E, et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 2006;77:193-198
84. Adab N, Jacoby A, Smith D, et al. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001;70:15-21
85. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004;62:28-32
86. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2004;75:1575-1583
87. Vinten J, Adab N, Kini U, et al. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005;64:949-954
88. Meador KJ, Baker G, Cohen MJ, et al. Cognitive/behavioral teratogenetic effects of antiepileptic drugs. Epilepsy Behav 2007;11:292-302
89. Tomson T, Battino D. Teratogenic effects of antiepileptic drugs. Seizure 2008;17:166-171
90. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 87 November 2007: use of psychiatric medications during pregnancy and lactation. Obstet Gynecol 2007 Nov;110(5):1179-1198
91. Cunnington M, Tennis P. Lamotrigine and the risk of malformations in pregnancy. Neurology 2005;64:955-960
92. Cunnington M, Ferber S, Quartey G. Effect of dose on the frequency of major birth defects following fetal exposure to lamotrigine monotherapy in an international observational study. Epilepsia 2007;48:1207-1210
93. Holmes LB, Wyszynski DF, Baldwin EJ, et al. Increased risk for non-syndromic cleft palate among infants exposed to lamotrigine during pregnancy. Presented at the 46th annual meeting of the Teratology Society; Jun 24-29, 2006; Tucson, Ariz
94. McKenna K, Koren G, Tetelbaum M, et al. Pregnancy outcome of women using atypical antipsychotic drugs: a prospective comparative study. J Clin Psychiatry 2005 Apr;66(4):444-449
95. Ernst CL, Goldberg JF. The reproductive safety profile of mood stabilizers, atypical antipsychotics, and broad-spectrum psychotropics. J Clin Psychiatry 2002;63(suppl 4):42-55
96. Yaeger D, Smith HG, Altshuler LL. Atypical antipsychotics in the treatment of schizophrenia during pregnancy and the postpartum. Am J Psychiatry 2006;163:2064-2070
97. Jones I, Craddock N. Bipolar disorder and childbirth: the importance of recognising risk. Br J Psychiatry 2005;186:453-454
98. Stewart DE, Klompenhouwer JL, Kendell RE, et al. Prophylactic lithium in puerperal psychosis: the experience of three centres. Br J Psychiatry 1991;158:393-397
99. Austin MP. Puerperal affective psychosis: is there a case for lithium prophylaxis? Br J Psychiatry 1992;161:692-694
100. Cohen LS, Sichel DA, Robertson LM, et al. Postpartum prophylaxis for women with bipolar disorder. Am J Psychiatry 1995;152:1641-1645
101. Wisner KL, Hanusa BH, Peindl KS, et al. Prevention of postpartum episodes in women with bipolar disorder. Biol Psychiatry 2004;56:592-596
102. Sharma V, Smith A, Mazmanian D. Olanzapine in the prevention of postpartum psychosis and mood episodes in bipolar disorder. Bipolar Disord 2006;8:400-404
103. Sichel DA, Cohen LS, Robertson LM, et al. Prophylactic estrogen in recurrent postpartum affective disorder. Biol Psychiatry 1995;38:814-818
104. Kumar C, McIvor RJ, Davies T, et al. Estrogen administration does not reduce the rate of recurrence of affective psychosis after childbirth. J Clin Psychiatry 2003 Feb;64(2):112-118
105. Stowe ZN. The use of mood stabilizers during breastfeeding. J Clin Psychiatry 2007;68(suppl 9):22-28
106. Newport DJ, Viguera AC, Beach AJ, et al. Lithium placental passage and obstetrical outcome: implications for clinical management during late pregnancy. Am J Psychiatry 2005;162:2162-2170
107. Burt VK, Suri R, Altshuler L, et al. The use of psychotropic medications during breast-feeding. Am J Psychiatry 2001;158:1001-1009
108. Chaudron LH, Jefferson JW. Mood stabilizers during breastfeeding: a review. J Clin Psychiatry 2000 Feb;61(2):79-90
109. Viguera AC, Newport DJ, Ritchie J, et al. Lithium in breast milk and nursing infants: clinical implications. Am J Psychiatry 2007;164:342-345